Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)Martin Reck, C. Manegold, J. Mezger et al.|Annals of Oncology|2010Cited by 644